This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AIDSVAX
Description: AIDSVAX is a bivalent vaccine consisting of a preparation of recombinant form of the protein, gp120, from two types of HIV.
Deal Structure: AIDSVAX was originally developed by Genentech. VaxGen (formerly Genenvax) was formed as a spin-off company from Genentech with the sole purpose of developing the vaccine.
In July 2002, VaxGen announced that the original License and Supply agreement with Genentech, signed in May 1997, had been amended. Under the revised agreement, Genentech maintains its right to market and sell AIDSVAX in North America, but has relinquished its options to commercialise the vaccine candidate in the rest of the world.
In November 2007, VaxGen and Raven announced that their respective boards of directors have unanimously approved a definitive merger agreement.
In March 2008, Vaxgen and Raven terminated their merger agreement in light of stronger than anticipated opposition to the proposed merger by VaxGen stockholders.
In March 2008, VaxGen formalized an agreement with Global Solutions forInfectious Diseases (GSID), a not-for-profit organization. Through this agreement, GSID has been...See full deal structure in Biomedtracker
Partners: Sanofi Roche Holding AG
Pink Sheet AIDS vaccine advisory committee
Additional information available to subscribers only: